PMID- 36878520 OWN - NLM STAT- MEDLINE DCOM- 20230313 LR - 20240201 IS - 2097-1109 (Print) IS - 2097-1109 (Linking) VI - 39 IP - 2 DP - 2023 Feb 20 TI - [A prospective study on application of human umbilical cord mesenchymal stem cells combined with autologous Meek microskin transplantation in patients with extensive burns]. PG - 114-121 LID - 10.3760/cma.j.cn501225-20220728-00319 [doi] AB - Objective: To investigate the effects of human umbilical cord mesenchymal stem cells (hUCMSCs) combined with autologous Meek microskin transplantation on patients with extensive burns. Methods: The prospective self-controlled study was conducted. From May 2019 to June 2022, 16 patients with extensive burns admitted to the 990(th) Hospital of PLA Joint Logistics Support Force met the inclusion criteria, while 3 patients were excluded according to the exclusion criteria, and 13 patients were finally selected, including 10 males and 3 females, aged 24-61 (42+/-13) years. A total of 20 trial areas (40 wounds, with area of 10 cmx10 cm in each wound) were selected. Two adjacent wounds in each trial area were divided into hUCMSC+gel group applied with hyaluronic acid gel containing hUCMSCs and gel only group applied with hyaluronic acid gel only according to the random number table, with 20 wounds in each group. Afterwards the wounds in two groups were transplanted with autologous Meek microskin grafts with an extension ratio of 1ratio6. In 2, 3, and 4 weeks post operation, the wound healing was observed, the wound healing rate was calculated, and the wound healing time was recorded. The specimen of wound secretion was collected for microorganism culture if there was purulent secretion on the wound post operation. In 3, 6, and 12 months post operation, the scar hyperplasia in wound was assessed using the Vancouver scar scale (VSS). In 3 months post operation, the wound tissue was collected for hematoxylin-eosin (HE) staining to observe the morphological changes and for immunohistochemical staining to observe the positive expressions of Ki67 and vimentin and to count the number of positive cells. Data were statistically analyzed with paired samples t test and Bonferronni correction. Results: In 2, 3, and 4 weeks post operation, the wound healing rates in hUCMSC+gel group were (80+/-11)%, (84+/-12)%, and (92+/-9)%, respectively, which were significantly higher than (67+/-18)%, (74+/-21)%, and (84+/-16)% in gel only group (with t values of 4.01, 3.52, and 3.66, respectively, P<0.05). The wound healing time in hUCMSC+gel group was (31+/-11) d, which was significantly shorter than (36+/-13) d in gel only group (t=-3.68, P<0.05). The microbiological culture of the postoperative wound secretion specimens from the adjacent wounds in 2 groups was identical, with negative results in 4 trial areas and positive results in 16 trial areas. In 3, 6, and 12 months post operation, the VSS scores of wounds in gel only group were 7.8+/-1.9, 6.7+/-2.1, and 5.4+/-1.6, which were significantly higher than 6.8+/-1.8, 5.6+/-1.6, and 4.0+/-1.4 in hUCMSC+gel group, respectively (with t values of -4.79, -4.37, and -5.47, respectively, P<0.05). In 3 months post operation, HE staining showed an increase in epidermal layer thickness and epidermal crest in wound in hUCMSC+gel group compared with those in gel only group, and immunohistochemical staining showed a significant increase in the number of Ki67 positive cells in wound in hUCMSC+gel group compared with those in gel only group (t=4.39, P<0.05), with no statistically significant difference in the number of vimentin positive cells in wound between the 2 groups (P>0.05). Conclusions: The application of hyaluronic acid gel containing hUCMSCs to the wound is simple to perform and is therefore a preferable route. Topical application of hUCMSCs can promote healing of the autologous Meek microskin grafted area in patients with extensive burns, shorten wound healing time, and alleviate scar hyperplasia. The above effects may be related to the increased epidermal thickness and epidermal crest, and active cell proliferation. FAU - Yan, T T AU - Yan TT AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Xiao, R AU - Xiao R AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Wang, Y AU - Wang Y AD - Beijing Zhongjing Hi-Tech Biotechnology Co., Beijing 100089, China. FAU - Lin, G A AU - Lin GA AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Zheng, Y AU - Zheng Y AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Zhao, H AU - Zhao H AD - Henan Cellular Industry Technology Research Institute Co., Zhengzhou 450121, China. FAU - Li, W J AU - Li WJ AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Shang, X Z AU - Shang XZ AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Meng, J S AU - Meng JS AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Hu, D S AU - Hu DS AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Li, S AU - Li S AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Wang, C AU - Wang C AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Lin, Z C AU - Lin ZC AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Chen, H C AU - Chen HC AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Zhao, D Y AU - Zhao DY AD - Military Burn Center, the 990th Hospital of PLA Joint Logistics Support Force, Zhumadian 463002, China. FAU - Tang, D AU - Tang D AD - Department of Burns & Plastic Surgery, PLA General Hospital of Central Theater Command, Wuhan 430012, China. LA - chi GR - 20QNPY074/Military Medical Science and Technology Youth Incubation Program/ PT - English Abstract PT - Journal Article PL - China TA - Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi JT - Zhonghua shao shang yu chuang mian xiu fu za zhi JID - 9918751287306676 RN - TDQ283MPCW (Eosine Yellowish-(YS)) RN - 9004-61-9 (Hyaluronic Acid) RN - 0 (Ki-67 Antigen) RN - 0 (Vimentin) SB - IM MH - Female MH - Humans MH - Male MH - *Burns/surgery MH - *Cicatrix MH - Eosine Yellowish-(YS) MH - Hyaluronic Acid/therapeutic use MH - Hyperplasia MH - Ki-67 Antigen MH - Prospective Studies MH - Umbilical Cord MH - Vimentin MH - Young Adult MH - Adult MH - Middle Aged EDAT- 2023/03/07 06:00 MHDA- 2023/03/09 06:00 CRDT- 2023/03/06 20:38 PHST- 2023/03/06 20:38 [entrez] PHST- 2023/03/07 06:00 [pubmed] PHST- 2023/03/09 06:00 [medline] AID - 10.3760/cma.j.cn501225-20220728-00319 [doi] PST - ppublish SO - Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023 Feb 20;39(2):114-121. doi: 10.3760/cma.j.cn501225-20220728-00319.